Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Codexis Inc (CDXS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 894,031
  • Shares Outstanding, K 54,020
  • Annual Sales, $ 50,020 K
  • Annual Income, $ -23,000 K
  • 36-Month Beta -1.60
  • Price/Sales 18.25
  • Price/Cash Flow N/A
  • Price/Book 16.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.01
  • Number of Estimates 2
  • High Estimate 0.01
  • Low Estimate -0.04
  • Prior Year 0.02
  • Growth Rate Est. (year over year) -150.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.05 +20.28%
on 10/24/18
17.49 -3.35%
on 11/09/18
+1.58 (+10.31%)
since 10/19/18
3-Month
14.05 +20.28%
on 10/24/18
19.60 -13.78%
on 09/26/18
+1.45 (+9.39%)
since 08/20/18
52-Week
5.85 +188.89%
on 11/21/17
19.60 -13.78%
on 09/26/18
+11.05 (+188.89%)
since 11/20/17

Most Recent Stories

More News
Codexis (CDXS) Reports Break-Even Earnings for Q3

Codexis (CDXS) delivered earnings and revenue surprises of 100.00% and 15.81%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

CDXS : 16.90 (+2.11%)
Codexis: 3Q Earnings Snapshot

REDWOOD CITY, Calif. (AP) _ Codexis Inc. (CDXS) on Thursday reported a loss of $2 million in its third quarter.

CDXS : 16.90 (+2.11%)
Codexis Reports Third Quarter 2018 Financial Results

Total revenues increase 70% to $16.9 million driven by higher product revenue and R&D revenue across an increased number of customers

CDXS : 16.90 (+2.11%)
Codexis Announces Results of Phase 1a Clinical Trial with CDX-6114

CDX-6114 meets safety and tolerability endpoints

CDXS : 16.90 (+2.11%)
Codexis to Present at Two Investment Conferences in November

Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at two upcoming investment conferences:

CDXS : 16.90 (+2.11%)
Will Codexis (CDXS) Report Negative Earnings Next Week? What You Should Know

Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CDXS : 16.90 (+2.11%)
Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Arsanis, Inc. (NASDAQ:ASNS),...

CDXS : 16.90 (+2.11%)
PBYI : 23.13 (+0.22%)
ASNS : 1.19 (-4.03%)
DVAX : 11.55 (+0.17%)
OPK : 3.54 (+2.61%)
ADAP : 5.48 (-3.01%)
Codexis Appoints Claus Ladefoged to Global Enzyme Business Development Role

Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the appointment of Claus Ladefoged as Director, Enzyme Business Development. Ladefoged has extensive experience in successfully...

CDXS : 16.90 (+2.11%)
NVO : 43.64 (-4.02%)
Guest Host Tonight

Guest Host Tonight

CDXS : 16.90 (+2.11%)
WK : 34.20 (-1.27%)
MLAB : 200.36 (-0.10%)
The Zacks Analyst Blog Highlights: AeroVironment, BioSpecifics, Codexis, Avid and American Outdoor

The Zacks Analyst Blog Highlights: AeroVironment, BioSpecifics, Codexis, Avid and American Outdoor

AOBC : 13.19 (-0.15%)
CDXS : 16.90 (+2.11%)
AVAV : 88.98 (-5.10%)
AVID : 6.16 (-2.84%)
BSTC : 56.22 (-3.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade CDXS with:

Business Summary

Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals. Codexis' proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective...

See More

Key Turning Points

2nd Resistance Point 17.67
1st Resistance Point 17.28
Last Price 16.90
1st Support Level 16.23
2nd Support Level 15.57

See More

52-Week High 19.60
Last Price 16.90
Fibonacci 61.8% 14.35
Fibonacci 50% 12.73
Fibonacci 38.2% 11.10
52-Week Low 5.85

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar